Exciting News Alert from Shilpa Medicare Limited!
We are thrilled to announce a significant milestone at Shilpa Medicare Limited!
“ Clinical Trial Announcement for SML 007”
Our groundbreaking drug, “SML-007”, designed to combat non-alcoholic fatty liver disease (NAFLD), has successfully completed its early clinical development phase and is now in the midst of an ongoing Phase 3 clinical trial.
What makes “SML-007” stand out? It’s an orally administered medication with revolutionary benefits surpassing conventional bile acid drugs. By reshaping bile acid synthesis and stimulating liver FXR signaling, it offers a promising pathway for NAFLD treatment. Moreover, its action through the adiponectin receptor pathway showcases unparalleled potential in combating inflammation and fibrosis.
Why is this significant? NAFLD affects a staggering 25% of the global population, with 14% progressing to the more severe non-alcoholic steatohepatitis (NASH), posing serious risks of liver fibrosis, cirrhosis, or Liver cancer.
Our dedication to advancing healthcare through innovation is evident in the development of SML-007, which holds the potential to revolutionize the treatment landscape for liver disease
Subscribe To Our Free Newsletter |